Genitourinary rhabdomyosarcoma: which treatment, how much, and when?

Area of Science:

• Pediatric Oncology
• Genitourinary Cancers
• Rhabdomyosarcoma Research

Background:

• Pediatric genitourinary rhabdomyosarcoma (RMS) is a rare but aggressive malignancy.
• Management strategies have evolved, with distinct approaches by major international study groups.
• Optimizing treatment while minimizing long-term side effects is a key challenge.

Purpose of the Study:

• To review and compare current management strategies for pediatric genitourinary rhabdomyosarcoma (RMS).
• To analyze treatment outcomes based on different therapeutic modalities, including surgery, chemotherapy, and radiotherapy.
• To identify key differences in protocols between major pediatric oncology study groups.

Main Methods:

• Review of studies from the Intergroup Rhabdomyosarcoma Study Group, Children's Oncology Group (COG), and International Society of Paediatric Oncology (SIOP) over the past decade.
• Comparative analysis of surgical, chemotherapeutic, and radiotherapeutic approaches for RMS treatment.
• Evaluation of associated patient outcomes, including overall and event-free survival rates.

Main Results:

• Equivalent overall survival rates were observed between recent COG and SIOP trials.
• SIOP trials reported worse event-free survival rates for bladder/prostate RMS compared to COG trials.
• Radiotherapy for local control emerged as a primary differentiator between COG and SIOP protocols; surgery is used for diagnosis and post-chemotherapy local control.

Conclusions:

• Ongoing research focuses on risk stratification and risk-based therapy to reduce treatment-related morbidity in pediatric RMS.
• The optimal role of surgery versus radiotherapy for local control remains under investigation.
• The benefits of additional second-line chemotherapy versus avoiding radiotherapy require further definition.